Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced …
Advanced MalignanciesOvarian CancerT-cell Lymphoma+1 more
BioInvent International ABNCT04752826
Phase 1
Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage inter-participant Dose Escalation Phase followed by a Dose Expansion Phase.
Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio LtdNCT06458712
Phase 1
An Open-Label Phase 1 Study to Evaluate PF-07994525 in Participants With Advanced Malignancies
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor …
Advanced MalignanciesAdvanced Cancer
PfizerNCT07426757
Phase 3
An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indicati…
Hematologic MalignancySolid TumorAdvanced Malignancies
Novartis PharmaceuticalsNCT06401356